Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
mi
from
Allentown, PA
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
mi
from
Allentown, PA
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
AnMed Cancer Center
mi
from
Anderson, SC
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
AnMed Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated:  7/9/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma
Status: Enrolling
Updated: 7/9/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns
Melanoma Survivors: Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns
Status: Enrolling
Updated:  7/15/2015
Memorial Sloan-Kettering Cancer Center 1275 York Avenue
mi
from
New York, NY
Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns
Melanoma Survivors: Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns
Status: Enrolling
Updated: 7/15/2015
Memorial Sloan-Kettering Cancer Center 1275 York Avenue
mi
from
New York, NY
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
University of Arizona Cancer Center
mi
from
Tucson, AZ
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
MSMC Research Program
mi
from
Miami Beach, FL
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
MSMC Research Program
mi
from
Miami Beach, FL
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
Oncology Specialists, SC
mi
from
Park Ridge, IL
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
Johns Hopkins Medicine
mi
from
Lutherville, MD
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
Johns Hopkins Medicine
mi
from
Lutherville, MD
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
Nebraska Cancer Specialists/Midwest Cancer Center - Legacy
mi
from
Omaha, NE
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
Nebraska Cancer Specialists/Midwest Cancer Center - Legacy
mi
from
Omaha, NE
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
Duke University Health System
mi
from
Durham, NC
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
The Christ Hospital
mi
from
Cincinnati, OH
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
Moores UCSD Cancer Center
mi
from
La Jolla, CA
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  7/15/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 7/15/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
Phase II Trial of Hyd-sulfate AZD6244 [NSC 748727] in Patients With BRAF or NRAS Mutated Melanomas
Status: Enrolling
Updated:  7/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
Phase II Trial of Hyd-sulfate AZD6244 [NSC 748727] in Patients With BRAF or NRAS Mutated Melanomas
Status: Enrolling
Updated: 7/16/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers
Culture and Characterization of Circulating Tumor Cells (CTC) From Patients With Malignant Melanoma and Other Cancers
Status: Enrolling
Updated:  7/18/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers
Culture and Characterization of Circulating Tumor Cells (CTC) From Patients With Malignant Melanoma and Other Cancers
Status: Enrolling
Updated: 7/18/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma
Phase I Trial of Immunization Using Particle-Mediated Transfer of Genes for GP-100 and GM-CSF Into Uninvolved Skin of Patients With Melanoma (Summary Last Modified 7/1999)
Status: Enrolling
Updated:  7/22/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma
Phase I Trial of Immunization Using Particle-Mediated Transfer of Genes for GP-100 and GM-CSF Into Uninvolved Skin of Patients With Melanoma (Summary Last Modified 7/1999)
Status: Enrolling
Updated: 7/22/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
Isolated Limb Perfusion for Advanced Melanoma or Sarcoma Limited to Extremity With or Without Distant Metastases
Status: Enrolling
Updated:  7/22/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
Isolated Limb Perfusion for Advanced Melanoma or Sarcoma Limited to Extremity With or Without Distant Metastases
Status: Enrolling
Updated: 7/22/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Mercy Capitol Hospital
mi
from
Des Moines, IA
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Mercy Capitol Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
mi
from
Des Moines, IA
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Medical Oncology and Hematology Associates at Mercy Cancer Center
mi
from
Des Moines, IA
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Medical Oncology and Hematology Associates at Mercy Cancer Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Mercy Cancer Center at Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Mercy Cancer Center at Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
John Stoddard Cancer Center at Iowa Lutheran Hospital
mi
from
Des Moines, IA
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
John Stoddard Cancer Center at Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
McCreery Cancer Center at Ottumwa Regional
mi
from
Ottumwa, IA
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
McCreery Cancer Center at Ottumwa Regional
mi
from
Ottumwa, IA
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Siouxland Hematology-Oncology Associates, LLP
mi
from
Sioux City, IA
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Siouxland Hematology-Oncology Associates, LLP
mi
from
Sioux City, IA
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
St. Luke's Regional Medical Center
mi
from
Sioux City, IA
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
St. Luke's Regional Medical Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Fairview Ridges Hospital
mi
from
Burnsville, MN
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Fairview Ridges Hospital
mi
from
Burnsville, MN
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Mercy and Unity Cancer Center at Mercy Hospital
mi
from
Coon Rapids, MN
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Mercy and Unity Cancer Center at Mercy Hospital
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated:  7/23/2015
Fairview Southdale Hospital
mi
from
Edina, MN
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Phase II Trial Evaluating Resection Followed By Adjuvant Radiation Therapy (RT) For Patients With Desmoplastic Melanoma
Status: Enrolling
Updated: 7/23/2015
Fairview Southdale Hospital
mi
from
Edina, MN
Click here to add this to my saved trials